CN111542513A - 用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物 - Google Patents

用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物 Download PDF

Info

Publication number
CN111542513A
CN111542513A CN201880084849.8A CN201880084849A CN111542513A CN 111542513 A CN111542513 A CN 111542513A CN 201880084849 A CN201880084849 A CN 201880084849A CN 111542513 A CN111542513 A CN 111542513A
Authority
CN
China
Prior art keywords
compound
imino
ethoxy
dihydrochloride
biindolinylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880084849.8A
Other languages
English (en)
Chinese (zh)
Inventor
金容哲
郑平和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pellemed Ltd
Original Assignee
Pellemed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pellemed Ltd filed Critical Pellemed Ltd
Publication of CN111542513A publication Critical patent/CN111542513A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880084849.8A 2017-10-31 2018-10-30 用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物 Pending CN111542513A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0144142 2017-10-31
KR20170144142 2017-10-31
PCT/KR2018/013051 WO2019088677A1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
CN111542513A true CN111542513A (zh) 2020-08-14

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084849.8A Pending CN111542513A (zh) 2017-10-31 2018-10-30 用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物

Country Status (12)

Country Link
US (1) US11370779B2 (https=)
EP (1) EP3705474A4 (https=)
JP (1) JP7005779B2 (https=)
KR (1) KR102247795B1 (https=)
CN (1) CN111542513A (https=)
AU (1) AU2018358582B2 (https=)
BR (1) BR112020008499A2 (https=)
CA (1) CA3080900C (https=)
MX (1) MX2020004374A (https=)
PH (1) PH12020550491A1 (https=)
RU (1) RU2763346C2 (https=)
WO (1) WO2019088677A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917290A (zh) * 2022-02-14 2023-10-20 佩勒梅德有限公司 具有新杂二环残基的靛玉红衍生物以及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433834B2 (en) 2019-04-26 2025-10-07 Conopco, Inc. Hair conditioning composition
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
CN114521142B (zh) * 2019-11-04 2024-07-02 Ck雷容股份有限公司 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
KR102296440B1 (ko) * 2019-12-06 2021-09-02 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
WO2024181799A1 (ko) * 2023-02-28 2024-09-06 주식회사 씨케이리제온 신규한 인돌린 유도체 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355789A (zh) * 1999-04-12 2002-06-26 格哈德·艾森布兰德 靛类双吲哚衍生物
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US20140275168A1 (en) * 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
CN105283456A (zh) * 2013-03-14 2016-01-27 希望之城 5-溴-靛玉红

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR100588803B1 (ko) 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
US8552053B2 (en) * 2005-12-23 2013-10-08 Centre National De La Recherche Scientifique 7-substituted indirubin-3′oximes and their applications
EP2149553B1 (en) * 2008-08-01 2011-10-19 Centre National de la Recherche Scientifique 3', 6-substituted indirubins and their biological applications
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US20150087687A1 (en) * 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355789A (zh) * 1999-04-12 2002-06-26 格哈德·艾森布兰德 靛类双吲哚衍生物
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US20140275168A1 (en) * 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
CN105283456A (zh) * 2013-03-14 2016-01-27 希望之城 5-溴-靛玉红
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOO JEONG CHOI等: ""Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells" *
XINLAI CHENG等: "Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917290A (zh) * 2022-02-14 2023-10-20 佩勒梅德有限公司 具有新杂二环残基的靛玉红衍生物以及其用途

Also Published As

Publication number Publication date
US20200270229A1 (en) 2020-08-27
CA3080900A1 (en) 2019-05-09
RU2020115581A (ru) 2021-12-02
RU2020115581A3 (https=) 2021-12-02
JP7005779B2 (ja) 2022-02-10
WO2019088677A1 (ko) 2019-05-09
JP2021501208A (ja) 2021-01-14
RU2763346C2 (ru) 2021-12-28
CA3080900C (en) 2022-10-25
AU2018358582B2 (en) 2021-06-10
AU2018358582A1 (en) 2020-05-07
KR20190049584A (ko) 2019-05-09
MX2020004374A (es) 2020-11-11
PH12020550491A1 (en) 2021-01-11
BR112020008499A2 (pt) 2020-10-20
EP3705474A1 (en) 2020-09-09
KR102247795B9 (ko) 2023-04-12
KR102247795B1 (ko) 2021-05-04
EP3705474A4 (en) 2021-06-09
US11370779B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
CN111542513A (zh) 用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物
AU2013230146B2 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as Raf kinase inhibitors
US6403588B1 (en) Imidazopyridine derivatives
CN113454081B (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
WO2001083481A1 (en) Imidazopyridine derivatives
JPWO2001083481A1 (ja) イミダゾピリジン誘導体
CA2800998A1 (en) Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN103930425A (zh) 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
EP2841062A1 (en) Methods and compositions for raf kinase mediated diseases
AU2014220300B2 (en) Quinazolines as kinase inhibitors
CN107151249A (zh) 作为flt3抑制剂的蝶啶酮衍生物及应用
TW202043221A (zh) Pde9抑制劑及其用途
CN103833759A (zh) 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用
WO2019029629A1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS
JP7201800B2 (ja) Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
KR20210047850A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
CN106467540B (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
US20150353524A1 (en) Pyridine compounds used as pi3 kinase inhibitors
CN109111439A (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
KR102682516B1 (ko) 퀴놀린 구조를 갖는 pan-kit 키나제 억제제 및 이의 용도
CN117304182A (zh) 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用
CN110283160B (zh) 一种pdgfr激酶抑制剂
CN116589464B (zh) 嘧啶并环类化合物、其制备方法和应用
CN120035595A (zh) 噻唑并[5,4-d]嘧啶化合物、包含其的组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination